JP2013530155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013530155A5 JP2013530155A5 JP2013512128A JP2013512128A JP2013530155A5 JP 2013530155 A5 JP2013530155 A5 JP 2013530155A5 JP 2013512128 A JP2013512128 A JP 2013512128A JP 2013512128 A JP2013512128 A JP 2013512128A JP 2013530155 A5 JP2013530155 A5 JP 2013530155A5
- Authority
- JP
- Japan
- Prior art keywords
- listeria
- cancer
- attenuated
- metabolically active
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34744710P | 2010-05-23 | 2010-05-23 | |
| US61/347,447 | 2010-05-23 | ||
| PCT/US2011/037602 WO2011149852A1 (en) | 2010-05-23 | 2011-05-23 | Methods and compositions using listeria for adjuvant treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016074013A Division JP6246252B2 (ja) | 2010-05-23 | 2016-04-01 | 癌の補助薬物療法でリステリアを使用する方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013530155A JP2013530155A (ja) | 2013-07-25 |
| JP2013530155A5 true JP2013530155A5 (cg-RX-API-DMAC7.html) | 2014-07-03 |
| JP5977737B2 JP5977737B2 (ja) | 2016-08-24 |
Family
ID=45004314
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013512128A Expired - Fee Related JP5977737B2 (ja) | 2010-05-23 | 2011-05-23 | 癌の補助薬物療法でリステリアを使用する方法および組成物 |
| JP2016074013A Expired - Fee Related JP6246252B2 (ja) | 2010-05-23 | 2016-04-01 | 癌の補助薬物療法でリステリアを使用する方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016074013A Expired - Fee Related JP6246252B2 (ja) | 2010-05-23 | 2016-04-01 | 癌の補助薬物療法でリステリアを使用する方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9161974B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2576791B8 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5977737B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102947452A (cg-RX-API-DMAC7.html) |
| ES (1) | ES2613630T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011149852A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
| US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
| US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
| AU2015253737A1 (en) * | 2014-05-02 | 2016-12-22 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
| WO2016073866A1 (en) * | 2014-11-07 | 2016-05-12 | The Johns Hopkins University | Polyfunctional lymphocytes as a biomarker of antitumor activity |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| AU2016369519B2 (en) | 2015-12-16 | 2023-04-20 | Seattle Project Corp. | Neoantigen identification, manufacture, and use |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| CN107213458A (zh) * | 2017-03-14 | 2017-09-29 | 中国人民解放军第三军医大学 | 一种使用载体组合的新型治疗性疫苗及使用方法 |
| CA3078744A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | Neoantigen identification using hotspots |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
| KR102637862B1 (ko) | 2017-12-13 | 2024-02-19 | 이노비오 파마수티컬즈, 인크. | 메소텔린을 표적으로 하는 암 백신 및 이의 용도 |
| CN108714210B (zh) * | 2018-08-06 | 2022-09-30 | 苏州圣苏新药开发有限公司 | 重组减毒李斯特菌在制备间皮素高表达癌症治疗性疫苗中的应用 |
| US12285437B2 (en) | 2019-10-30 | 2025-04-29 | The Research Foundation For The State University Of New York | Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| US6051237A (en) * | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| US20020150588A1 (en) | 2000-09-21 | 2002-10-17 | Allison James P. | SPAS-1 cancer antigen |
| WO2004006837A2 (en) | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| AU2004224425B2 (en) | 2003-02-06 | 2010-06-24 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
| KR101192652B1 (ko) | 2003-02-06 | 2012-10-19 | 앤저 테라퓨틱스 인코퍼레이티드 | 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법 |
| US20050281783A1 (en) | 2003-10-15 | 2005-12-22 | Kinch Michael S | Listeria-based EphA2 vaccines |
| US7842289B2 (en) | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
| CA2613012A1 (en) * | 2005-06-23 | 2007-01-04 | Arbor Vita Corporation | Methods and compositions for modulating cox |
| US20070190029A1 (en) * | 2005-08-19 | 2007-08-16 | Cerus Corporation | Listeria-induced immunorecruitment and activation, and methods of use thereof |
| EP1991263B8 (en) * | 2006-03-01 | 2015-02-25 | Aduro Biotech | Engineered listeria and methods of use thereof |
| US20070207171A1 (en) * | 2006-03-01 | 2007-09-06 | Cerus Corporation | Engineered listeria and methods of use thereof |
| US7935804B2 (en) * | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
| WO2008094188A2 (en) | 2006-07-17 | 2008-08-07 | Anza Therapeutics, Inc. | Methods and compositions using listeria for enhancing immunogenicity by prime boost |
| US8268326B2 (en) * | 2006-08-15 | 2012-09-18 | The Trustees Of The University Of Pennsylvania | Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof |
| CN102076843A (zh) | 2008-05-19 | 2011-05-25 | 艾杜罗生物科技公司 | 包含prfa*突变体李斯特菌的组合物及其使用方法 |
-
2011
- 2011-05-23 CN CN2011800304209A patent/CN102947452A/zh active Pending
- 2011-05-23 JP JP2013512128A patent/JP5977737B2/ja not_active Expired - Fee Related
- 2011-05-23 EP EP11787200.2A patent/EP2576791B8/en not_active Not-in-force
- 2011-05-23 WO PCT/US2011/037602 patent/WO2011149852A1/en not_active Ceased
- 2011-05-23 ES ES11787200.2T patent/ES2613630T3/es active Active
- 2011-05-23 US US13/699,687 patent/US9161974B2/en not_active Expired - Fee Related
-
2016
- 2016-04-01 JP JP2016074013A patent/JP6246252B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013530155A5 (cg-RX-API-DMAC7.html) | ||
| Lemay et al. | Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine | |
| NZ616304A (en) | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses | |
| IN2015DN00376A (cg-RX-API-DMAC7.html) | ||
| JP2012046524A5 (cg-RX-API-DMAC7.html) | ||
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| MY191040A (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
| MX374870B (es) | Inhalador de polvo seco. | |
| Zhen et al. | CRISPR/Cas9‐HPV‐liposome enhances antitumor immunity and treatment of HPV infection‐associated cervical cancer | |
| WO2016030760A3 (en) | Treatment of inflammation, respiratory tract infections and cystic fibrosis | |
| AU2010300611A8 (en) | Hematopoietic stem cells for use in the treatment of a kidney injury | |
| JP2013537426A5 (cg-RX-API-DMAC7.html) | ||
| HK1222134A1 (zh) | 治疗人的实体肿瘤的诺氏梭菌 | |
| MX358680B (es) | Usos de inmunoconjugados dirigidos a cd138. | |
| MX2021006751A (es) | Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. | |
| WO2015095167A3 (en) | Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon | |
| WO2010086838A3 (en) | Non-ad5 adenoviral vectors and methods and uses related thereto | |
| MX2021003826A (es) | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. | |
| Chami et al. | Radiation and immune checkpoint inhibitors: combination therapy for treatment of hepatocellular carcinoma | |
| Yin et al. | Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo | |
| Navarro-Ocon et al. | Nanomedicine as a promising tool to overcome immune escape in breast cancer | |
| MY186840A (en) | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy | |
| Dosset et al. | Modulation of determinant factors to improve therapeutic combinations with immune checkpoint inhibitors |